A1 Discount Vitamins – FDA Warning Letter

The FDA issued a Warning Letter to A1 Discount Vitamins following a review of their website, www.a1discountvitamins.com. The agency determined that several products, including "C-1000," "Colloidal Silver," "Graviola," "Red Raspberry Extract," "Juice Complex," "Lycopene," and "Pomegranate," are promoted with therapeutic claims that cause them to be unapproved new drugs and misbranded. Examples of claims cited include preventing and fighting various cancers, acting as an antibiotic, and treating conditions like AIDS, diabetes, and heart disease. These claims establish the products as drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act).

Specifically, the products are considered "new drugs" under section 201(p) of the Act because they are not generally recognized as safe and effective for their intended uses. Marketing new drugs in the U.S. requires prior FDA approval under section 505(a), which the firm lacks. Furthermore, these products are misbranded under section 502(f)(1) of the Act because their labeling fails to bear adequate directions for use. The letter emphasizes that using scientific publications commercially to promote products for disease treatment or prevention also constitutes claims. A1 Discount Vitamins is required to take prompt action to correct these violations, review all promotional materials, and respond to the FDA within fifteen working days, detailing corrective steps or a timeline for completion. Failure to comply may lead to enforcement actions, including product seizure and injunctions.